First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease
Latest Information Update: 03 Oct 2021
At a glance
- Drugs FLYSYN (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Acronyms FLYSYN-101
- Sponsors Synimmune
- 27 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results (updated results) from this study, were presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 03 Apr 2020 Status changed from recruiting to active, no longer recruiting.